Why Some Ultra-Processed Foods Go Down So Easily, So Fast
New research is helping to answer an important question about ultra-processed foods: Which ones may be healthier?
One reason many ultra–processed foods often lead us to eat big meals and heavy snacks is because of their texture, which makes them go down easily and quickly, according to a new study presented this week at a conference of the American Society for Nutrition in Orlando, Fla.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
If You Invested $10K In Equity LifeStyle Stock 10 Years Ago, How Much Would You Have Now?
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Equity LifeStyle Properties Inc. (NYSE:ELS) is a real estate investment trust owning and operating manufactured home communities, RV resorts and campgrounds in North America. The company's stock traded at approximately $27.63 per share 10 years ago. If you had invested $10,000, you could have bought roughly 362 shares. Currently, shares trade at $63.07, meaning your investment's value could have grown to $22,827 from stock price appreciation alone. However, Equity LifeStyle also paid dividends during these 10 years. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can Equity LifeStyle's dividend yield is currently 3.29%. Over the last 10 years, it has paid about $13.08 in dividends per share, which means you could have made $4,734 from dividends alone. Summing up $22,827 and $4,734, we end up with the final value of your investment, which is $27,561. This is how much you could have made if you had invested $10,000 in Equity LifeStyle stock 10 years ago. This means a total return of 175.61%. However, this figure is significantly less than the S&P 500 total return for the same period, which was 238.79%. Equity LifeStyle has a consensus rating of "Outperform" and a price target of $73.23 based on the ratings of 13 analysts. The price target implies a more than 16% potential upside from the current stock price. Trending: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. The company on April 21 announced its Q1 2025 earnings, posting FFO of $0.83, in line with expectations, while revenues of $387.33 million missed the consensus estimate of $398.72 million, as reported by Benzinga. For full-year 2025, the company expects net income per common share in the range of $1.97 to $2.07, and FFO per share of $3.01 to $3.11. Check out this article by Benzinga for five analysts' insights on Equity LifeStyle Properties. Given the expected upside potential, growth-focused investors may find Equity LifeStyle stock attractive. Furthermore, they can benefit from the company's solid dividend yield of 3.29%. Read Next: Maximize saving for your retirement and cut down on taxes: . , which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. Image: Shutterstock This article If You Invested $10K In Equity LifeStyle Stock 10 Years Ago, How Much Would You Have Now? originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Here's what to know about the twice-yearly preventative HIV shot
The Food and Drug Administration has approved a twice-yearly preventive HIV shot that could protect millions from the virus. People at risk for HIV may choose to take PrEP, a medication that helps prevent HIV infection. PrEp has been prescribed as a daily pill or a shot given every two months. This new twice-yearly drug called lenacapavir is now the longest-lasting type of PrEP. Ian Haddock, a Houston man who participated in a study of the drug, told The Associated Press it 'expands the opportunity for prevention.' 'Now I forget that I'm on PrEP because I don't have to carry around a pill bottle,' he said. The shot, made by Gilead Sciences, is injected under the skin of the abdomen. It leaves a small 'depot' of medication that slowly absorbs into the body. 'This really has the possibility of ending HIV transmission,' Greg Millett, public policy director at amfAR, The Foundation for AIDS Research, told the AP. But the upheaval in U.S. healthcare — including cuts to public health agencies and Medicaid — and slashing of American foreign aid to fight HIV are clouding the prospects. Millett said "gaping holes in the system" in the U.S. and globally "are going to make it difficult for us to make sure we not only get lenacapavir into people's bodies but make sure they come back' even as little as twice a year. Gilead's drug already is sold to treat HIV under the brand name Sunlenca. The prevention dose will be sold under a different name, Yeztugo. Gilead didn't immediately announce its price. The drug only prevents HIV transmission – it doesn't block other sexually transmitted diseases. Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide. Only about 400,000 Americans already use some form of PrEP, a fraction of those estimated to benefit. A recent study found states with high use of PrEP saw a decrease in HIV infections, while rates continued rising elsewhere. About half of new infections are in women, who often need protection they can use without a partner's knowledge or consent. One rigorous study in South Africa and Uganda compared more than 5,300 sexually active young women and teen girls given twice-yearly lenacapavir or the daily pills. There were no HIV infections in those receiving the shot while about 2% in the comparison group caught HIV from infected sex partners. A second study found the twice-yearly shot nearly as effective in gay men and gender-nonconforming people in the U.S. and in several other countries hard-hit by HIV. Haddock, who leads the Normal Anomaly Initiative, a nonprofit serving Black LGBTQ+ communities, had tried PrEP off and on since 2015 but he jumped at the chance to participate in the lenacapavir study and continues with the twice-yearly shots as part of the research follow-up. 'Men, women, gay, straight – it really just kinds of expands the opportunity for prevention,' he added. Just remembering a clinic visit every six months 'is a powerful tool versus constantly having to talk about, like, condoms, constantly making sure you're taking your pill every day.' 'Everyone in every country who's at risk of HIV needs access to PrEP,' Dr. Gordon Crofoot of Houston, who helped lead the study in men, told the AP. 'We need to get easier access to PrEP that's highly effective like this is.'
CBS News
an hour ago
- CBS News
Pandemic-era puppies, kittens now filling San Francisco shelters beyond capacity
The COVID-19 pandemic is still having a deadly effect on the pet population. The number of unwanted animals is straining San Francisco's shelter capacity to the breaking point, sometimes with tragic results. Just about every animal shelter in the state is jammed these days and it all points back to the pandemic when shelters were empty and it was hard to find any animal to adopt, as people tried to cope with COVID isolation. But also at that time, spaying and neutering were suspended or drastically reduced. And now those generations of puppies and kittens are filling the shelters. "So, not just in San Francisco, but in California and nationwide, we are like two million spay/neuters behind. So, that just leads to more and more accidental breeding," said Virginia Donohue, Executive Director of San Francisco's Animal Care and Control. "Pre-pandemic, we were full a couple times a year. Now we're full a couple times a month. It is a constant problem. It's no longer an occasional problem." And it can have heartbreaking consequences. SF Animal Care and Control works to find unwanted pets a home, but when none is available, they must turn to euthanasia to make room. "We try very hard to euthanize just for medical and behavior issues," said Donohue. "But there are points when an animal is here too long and nobody is coming for it, we don't have a place for it to go and its behavior is deteriorating. Then we're going to euthanasia." One of the reasons the city's public animal shelter is so full is because its major adoption partner, the San Francisco SPCA, is taking a lot fewer dogs and cats than it used to. The SF SPCA, which is a private entity, has joined forces with the Stockton SPCA and is now rescuing a lot more unwanted pets from the Central Valley. "Historically, they've taken as many as 600 dogs," said SF's Donohue. "Currently, it's under 200. So, obviously, that's a pain point." It's also a reason why Animal Care and Control is having to turn to euthanasia. Another is that the shelter has a "custody" program that holds dogs up to two weeks for people who go to jail or the hospital or who die. That all takes space from those pets looking to be adopted. On Saturday, a dog owner named Ethan said he sometimes wonders where they're all coming from. "To see the amount of people out there that have dogs that aren't taking care of them, like, I don't really understand how they got these dogs in the first place," he said. The dogs are out there, many in desperate need of a caring home. But there is only so much space in the shelters and reducing the population is now more than just a humane thing to do. It's becoming a matter of life and death. "I mean, don't get a dog if you weren't intending to get a dog," Donohue said. "But if you want a dog, just look at your local shelter first. Even if you don't find the dog of your dreams there, just look and see what's available."
